Physician profile
Phuc T Le
NPI 1396953998
$5,446.91
in general payments reported to CMS, 2019-2025
22 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2021: $196 · 2022: $105 · 2023: $3,582 · 2024: $671 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Travel and Lodging: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.23 |
| Travel and Lodging | $2,365.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,163.61 | 2022-2024 | Cardiomems |
| Medtronic, INC. | $1,909.56 | 2021-2023 | Venaseal |
| Astrazeneca Pharmaceuticals LP | $201.37 | 2024-2025 | Lokelma, Wainua |
| Edwards Lifesciences Corporation | $187.03 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $165.91 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $123.10 | 2024-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.21 | 2023-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $97.59 | 2025 | Assure Wcd |
| Amgen INC. | $81.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.11 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $62.90 | 2019-2024 | Xarelto |
| Bardy Diagnostics, INC. | $45.00 | 2021-2022 | |
| Novo Nordisk INC | $40.29 | 2024 | Ozempic |
| Amarin Pharma, INC. | $33.73 | 2019 | |
| Pfizer INC. | $30.23 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $22.09 | 2024 | Barostim Neo System |
| Bridgebio Pharma, INC. | $20.30 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $18.38 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2019 | |
| Esperion Therapeutics, INC. | $17.85 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $16.41 | 2019 | |
| Boston Scientific Corporation | $15.67 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuc Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.